tiprankstipranks
Blurbs

Alkermes (ALKS) Receives a Hold from SVB Securities

SVB Securities analyst Marc Goodman maintained a Hold rating on Alkermes (ALKSResearch Report) on July 11 and set a price target of $27.00. The company’s shares closed last Thursday at $29.05.

According to TipRanks.com, Goodman is a 3-star analyst with an average return of 1.1% and a 47.8% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

Alkermes has an analyst consensus of Hold, with a price target consensus of $30.40.

See today’s best-performing stocks on TipRanks >>

Alkermes’ market cap is currently $4.82B and has a P/E ratio of -76.37.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Read More on ALKS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More